 Jessica Rove
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 7 | 2024 | 671 | 2.680 |
Why?
| | Cardiac Surgical Procedures | 5 | 2024 | 415 | 2.530 |
Why?
| | Tissue and Organ Procurement | 6 | 2024 | 243 | 1.700 |
Why?
| | Extracorporeal Membrane Oxygenation | 5 | 2023 | 242 | 1.350 |
Why?
| | Educational Personnel | 1 | 2022 | 13 | 0.830 |
Why?
| | Lidocaine | 1 | 2022 | 41 | 0.820 |
Why?
| | Gelatin | 1 | 2022 | 36 | 0.820 |
Why?
| | Mitral Valve Insufficiency | 1 | 2022 | 62 | 0.780 |
Why?
| | Heart Valve Prosthesis | 1 | 2023 | 122 | 0.770 |
Why?
| | General Surgery | 1 | 2022 | 129 | 0.740 |
Why?
| | Organ Preservation | 4 | 2024 | 67 | 0.740 |
Why?
| | Vascular Grafting | 1 | 2020 | 12 | 0.730 |
Why?
| | Echocardiography | 1 | 2022 | 563 | 0.680 |
Why?
| | Phospholipases A2, Secretory | 4 | 2019 | 23 | 0.680 |
Why?
| | Perfusion | 5 | 2024 | 151 | 0.670 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2022 | 175 | 0.670 |
Why?
| | Thoracic Surgery | 1 | 2020 | 105 | 0.660 |
Why?
| | Surgeons | 1 | 2023 | 238 | 0.660 |
Why?
| | Esophageal Neoplasms | 3 | 2017 | 273 | 0.610 |
Why?
| | Stomach Diseases | 1 | 2017 | 19 | 0.570 |
Why?
| | Anastomosis, Surgical | 1 | 2017 | 140 | 0.550 |
Why?
| | Esophagectomy | 1 | 2017 | 111 | 0.530 |
Why?
| | Cognition | 1 | 2023 | 982 | 0.530 |
Why?
| | Deglutition Disorders | 1 | 2017 | 119 | 0.510 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 607 | 0.510 |
Why?
| | Enzyme Inhibitors | 4 | 2013 | 753 | 0.510 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 757 | 0.490 |
Why?
| | Reoperation | 1 | 2017 | 524 | 0.480 |
Why?
| | Internship and Residency | 2 | 2020 | 951 | 0.480 |
Why?
| | Tissue Donors | 4 | 2024 | 330 | 0.480 |
Why?
| | Humans | 42 | 2024 | 115222 | 0.450 |
Why?
| | Group II Phospholipases A2 | 2 | 2012 | 19 | 0.420 |
Why?
| | Retrospective Studies | 13 | 2024 | 12597 | 0.420 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 1731 | 0.420 |
Why?
| | Quality of Life | 1 | 2023 | 2364 | 0.410 |
Why?
| | Lung Neoplasms | 5 | 2019 | 2200 | 0.410 |
Why?
| | Postoperative Complications | 2 | 2017 | 2158 | 0.360 |
Why?
| | Bronchiectasis | 2 | 2012 | 107 | 0.350 |
Why?
| | Pneumonectomy | 2 | 2012 | 125 | 0.350 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2012 | 962 | 0.350 |
Why?
| | Heart | 2 | 2023 | 613 | 0.330 |
Why?
| | United States | 7 | 2024 | 12256 | 0.300 |
Why?
| | Lung Transplantation | 2 | 2024 | 246 | 0.300 |
Why?
| | NF-kappa B | 5 | 2012 | 637 | 0.300 |
Why?
| | Adult | 13 | 2024 | 30711 | 0.290 |
Why?
| | Apoptosis | 4 | 2013 | 2368 | 0.290 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 337 | 0.280 |
Why?
| | Brain Death | 2 | 2024 | 32 | 0.280 |
Why?
| | Osteogenesis | 2 | 2012 | 183 | 0.270 |
Why?
| | Thoracic Surgical Procedures | 2 | 2024 | 56 | 0.270 |
Why?
| | Adenocarcinoma | 3 | 2013 | 795 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2022 | 9151 | 0.250 |
Why?
| | Intercellular Adhesion Molecule-1 | 3 | 2019 | 154 | 0.250 |
Why?
| | Cell Proliferation | 3 | 2013 | 2192 | 0.250 |
Why?
| | Consensus | 2 | 2024 | 534 | 0.250 |
Why?
| | Organ Transplantation | 2 | 2024 | 161 | 0.240 |
Why?
| | Aortic Valve Stenosis | 2 | 2012 | 272 | 0.240 |
Why?
| | Aortic Valve | 2 | 2012 | 397 | 0.240 |
Why?
| | RNA Interference | 2 | 2012 | 437 | 0.230 |
Why?
| | Organ Preservation Solutions | 1 | 2023 | 41 | 0.220 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 32 | 0.220 |
Why?
| | Coronary Artery Bypass | 2 | 2024 | 196 | 0.220 |
Why?
| | American Heart Association | 1 | 2024 | 264 | 0.210 |
Why?
| | Biglycan | 1 | 2012 | 7 | 0.210 |
Why?
| | Travel | 1 | 2023 | 121 | 0.210 |
Why?
| | Hernia, Inguinal | 1 | 2012 | 27 | 0.200 |
Why?
| | Herniorrhaphy | 1 | 2012 | 50 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 247 | 0.200 |
Why?
| | Echocardiography, Transesophageal | 1 | 2022 | 89 | 0.200 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 109 | 0.200 |
Why?
| | Jugular Veins | 1 | 2012 | 38 | 0.200 |
Why?
| | Hypothermia, Induced | 1 | 2022 | 69 | 0.200 |
Why?
| | ras Proteins | 1 | 2012 | 138 | 0.200 |
Why?
| | Time Factors | 5 | 2023 | 6157 | 0.200 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 299 | 0.190 |
Why?
| | Spinal Cord Ischemia | 1 | 2022 | 63 | 0.190 |
Why?
| | Technology Transfer | 1 | 2021 | 13 | 0.190 |
Why?
| | Computed Tomography Angiography | 1 | 2022 | 100 | 0.190 |
Why?
| | Death | 1 | 2022 | 109 | 0.190 |
Why?
| | Pulmonary Valve Insufficiency | 1 | 2012 | 42 | 0.190 |
Why?
| | Mitral Valve | 1 | 2022 | 86 | 0.190 |
Why?
| | Thoracotomy | 2 | 2017 | 67 | 0.190 |
Why?
| | Graft Survival | 1 | 2023 | 479 | 0.190 |
Why?
| | Genetic Therapy | 1 | 2012 | 258 | 0.190 |
Why?
| | Bronchi | 1 | 2012 | 243 | 0.180 |
Why?
| | Pain, Postoperative | 1 | 2022 | 194 | 0.180 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2011 | 40 | 0.180 |
Why?
| | Seizures | 1 | 2023 | 341 | 0.180 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2022 | 122 | 0.180 |
Why?
| | Coronary Circulation | 1 | 2020 | 135 | 0.180 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 53 | 0.180 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2022 | 182 | 0.170 |
Why?
| | Calcinosis | 1 | 2012 | 242 | 0.170 |
Why?
| | Phosphorylation | 5 | 2013 | 1574 | 0.170 |
Why?
| | Graft Rejection | 1 | 2023 | 532 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 222 | 0.170 |
Why?
| | Blotting, Western | 5 | 2013 | 1150 | 0.170 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2021 | 152 | 0.160 |
Why?
| | Heart Arrest | 1 | 2022 | 289 | 0.160 |
Why?
| | Blood Flow Velocity | 1 | 2020 | 395 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 609 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1214 | 0.160 |
Why?
| | Mental Health | 1 | 2024 | 559 | 0.160 |
Why?
| | Health Personnel | 1 | 2024 | 575 | 0.160 |
Why?
| | Phylogeny | 1 | 2022 | 796 | 0.160 |
Why?
| | Dinoprostone | 1 | 2019 | 185 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 146 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 164 | 0.150 |
Why?
| | Cell Movement | 1 | 2012 | 866 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 292 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 577 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1882 | 0.140 |
Why?
| | Cell Line, Tumor | 5 | 2012 | 2715 | 0.140 |
Why?
| | Gastric Emptying | 1 | 2017 | 40 | 0.140 |
Why?
| | Anxiety | 1 | 2023 | 846 | 0.140 |
Why?
| | Delivery of Health Care | 1 | 2023 | 836 | 0.140 |
Why?
| | Laparotomy | 1 | 2017 | 97 | 0.140 |
Why?
| | Hospital Mortality | 1 | 2020 | 776 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 928 | 0.130 |
Why?
| | Hydrogels | 1 | 2022 | 575 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 386 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2012 | 666 | 0.130 |
Why?
| | Aged | 7 | 2021 | 19136 | 0.120 |
Why?
| | Asphyxia | 1 | 2014 | 21 | 0.120 |
Why?
| | Middle Aged | 8 | 2024 | 26873 | 0.120 |
Why?
| | Clinical Competence | 1 | 2020 | 904 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1765 | 0.110 |
Why?
| | Veterans | 1 | 2024 | 1234 | 0.110 |
Why?
| | Mutation | 1 | 2012 | 3350 | 0.100 |
Why?
| | Thoracoscopy | 2 | 2012 | 53 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2012 | 127 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2012 | 1860 | 0.090 |
Why?
| | Male | 10 | 2024 | 55814 | 0.090 |
Why?
| | RNA, Messenger | 3 | 2012 | 2563 | 0.090 |
Why?
| | Transfection | 2 | 2012 | 872 | 0.090 |
Why?
| | Aorta, Thoracic | 2 | 2022 | 261 | 0.090 |
Why?
| | Mice | 2 | 2022 | 14934 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4645 | 0.080 |
Why?
| | Female | 8 | 2024 | 59720 | 0.080 |
Why?
| | Bone Morphogenetic Protein 2 | 2 | 2012 | 75 | 0.080 |
Why?
| | Patient Selection | 2 | 2012 | 651 | 0.080 |
Why?
| | Alkaline Phosphatase | 2 | 2012 | 144 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 372 | 0.070 |
Why?
| | Animals | 3 | 2022 | 31884 | 0.070 |
Why?
| | Databases, Factual | 2 | 2020 | 1136 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2021 | 6358 | 0.070 |
Why?
| | Prognosis | 2 | 2024 | 3336 | 0.060 |
Why?
| | Cell Survival | 2 | 2012 | 1022 | 0.060 |
Why?
| | Donor Selection | 1 | 2024 | 73 | 0.060 |
Why?
| | Tissue and Organ Harvesting | 1 | 2024 | 69 | 0.060 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 20 | 0.050 |
Why?
| | Signal Transduction | 3 | 2013 | 4527 | 0.050 |
Why?
| | Cell Growth Processes | 1 | 2012 | 51 | 0.050 |
Why?
| | Workplace | 1 | 2024 | 220 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 104 | 0.050 |
Why?
| | Surgical Mesh | 1 | 2012 | 42 | 0.050 |
Why?
| | Paraplegia | 1 | 2022 | 52 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2012 | 129 | 0.050 |
Why?
| | Occupational Health | 1 | 2024 | 164 | 0.050 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 157 | 0.050 |
Why?
| | Tumor Burden | 1 | 2012 | 260 | 0.050 |
Why?
| | Blood Vessel Prosthesis | 1 | 2022 | 113 | 0.050 |
Why?
| | Airway Management | 1 | 2012 | 60 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 262 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 228 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 271 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2012 | 222 | 0.050 |
Why?
| | Mice, Nude | 1 | 2012 | 631 | 0.050 |
Why?
| | Organ Size | 1 | 2012 | 444 | 0.050 |
Why?
| | Antitubercular Agents | 1 | 2012 | 169 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2012 | 3897 | 0.050 |
Why?
| | Anesthesia | 1 | 2012 | 118 | 0.050 |
Why?
| | Vascular Patency | 1 | 2020 | 97 | 0.050 |
Why?
| | Cerebrovascular Circulation | 1 | 2022 | 225 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 443 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2024 | 557 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 697 | 0.040 |
Why?
| | Down-Regulation | 1 | 2012 | 599 | 0.040 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 398 | 0.040 |
Why?
| | Syndrome | 1 | 2011 | 338 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 221 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 286 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 347 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1377 | 0.040 |
Why?
| | Postoperative Care | 1 | 2011 | 222 | 0.040 |
Why?
| | Cattle | 1 | 2012 | 925 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1171 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 51 | 0.040 |
Why?
| | Burnout, Professional | 1 | 2024 | 321 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2012 | 1231 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 410 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 900 | 0.040 |
Why?
| | Stents | 1 | 2022 | 476 | 0.040 |
Why?
| | Biomarkers | 2 | 2012 | 3422 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2022 | 618 | 0.040 |
Why?
| | Risk | 1 | 2020 | 816 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 174 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1145 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1436 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1458 | 0.030 |
Why?
| | Lung Diseases | 1 | 2012 | 703 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2012 | 3023 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2024 | 4430 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2083 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 2900 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 1968 | 0.030 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 929 | 0.030 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2012 | 41 | 0.030 |
Why?
| | Osteopontin | 1 | 2012 | 32 | 0.030 |
Why?
| | Hypertension | 1 | 2020 | 1060 | 0.030 |
Why?
| | Pravastatin | 1 | 2011 | 28 | 0.020 |
Why?
| | Adolescent | 2 | 2023 | 17889 | 0.020 |
Why?
| | Radiotherapy | 1 | 2012 | 176 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 4917 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2011 | 60 | 0.020 |
Why?
| | Simvastatin | 1 | 2011 | 59 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2344 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 851 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 401 | 0.020 |
Why?
| | Pyrroles | 1 | 2011 | 183 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 812 | 0.020 |
Why?
| | Infant | 1 | 2012 | 7966 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 500 | 0.020 |
Why?
| | Child, Preschool | 1 | 2012 | 9124 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1084 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1138 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 2814 | 0.020 |
Why?
| | Child | 1 | 2012 | 18468 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 10520 | 0.010 |
Why?
|
|
Rove's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|